Jagdip S Sidhu

Suggest Changes
Learn More
OBJECTIVES We sought to assess the effect of rosiglitazone on markers of endothelial cell activation and acute-phase reactants in non-diabetic patients with coronary artery disease (CAD). (More)
BACKGROUND Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, is used in the treatment of type 2 diabetes mellitus, and in vitro data has shown that it may have(More)
  • 1